Clinical Report: Can Gene Therapy Deliver Durability?

Overview

Emerging data from late-stage intravitreal gene therapies for neovascular age-related macular degeneration (nAMD) suggest potential for reduced injection burden and sustained visual acuity. Key programs, including ixoberogene soroparvovec and 4D-150, show promising durability and safety profiles.

Background

The management of nAMD has traditionally relied on frequent anti-VEGF injections, which can be burdensome for patients. As durability of treatment becomes a central focus, gene therapy offers a novel approach that may reduce the frequency of injections while maintaining visual outcomes. Understanding the efficacy and safety of these therapies is crucial for optimizing patient care.

Data Highlights

No numerical data available in the source material.

Key Findings

• Durability is a significant unmet need in nAMD treatment, with gene therapy viewed as a promising solution.
• The ixoberogene soroparvovec program has shown detectable aflibercept expression and stable visual acuity over 5 years.
• The phase 2 LUNA study indicated lower doses of Ixo-vec resulted in reduced inflammation and maintained visual stability.
• 4D-150 demonstrated a durable reduction in supplemental injection requirements and maintained vision in refractory nAMD patients.
• Safety profiles for both Ixo-vec and 4D-150 have improved with evolving dose selection and steroid prophylaxis strategies.

Clinical Implications

Healthcare professionals should consider the potential of gene therapy to reduce the treatment burden for patients with nAMD. Ongoing monitoring of safety and efficacy in real-world settings will be essential to determine the practical application of these therapies.

Conclusion

Gene therapy represents a promising advancement in the treatment of nAMD, with the potential to enhance durability and reduce injection frequency. Continued research and clinical trials will be critical in validating these findings.

Related Resources & Content

1. Adverum Gene-derived Anti-VEGF Proves Highly Durable, Retinal Physician, 2020 -- Wet AMD patient goes 92 weeks without retreatment.
2. Introduction to gene therapy, Ophthalmic Professional, 2020 -- A review of the basic principles of genetic testing, types of gene therapy, and administration.
3. UPFRONT: Gene Therapy's Price Tag, Retinal Physician, 2023 -- Gene therapy is a hot topic across all fields of medicine.
4. The Eye as a Biofactory, Retinal Physician, 2020 -- A special issue on gene therapy.
5. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed, 2023 -- Guideline-based care for nAMD.
6. 4DMT Presents Positive 52-Week Results From Phase 2b Cohort of PRISM Wet AMD Study, Ophthalmology Management, 2025 -- A single intravitreal dose achieved an 83% reduction in supplemental injections.
7. Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD, Adverum Biotechnologies, 2025 -- Initiation of phase 3 study for Ixo-vec.
8. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
9. 4DMT Presents Positive 52-Week Results From Phase 2b Cohort of PRISM Wet AMD Study | Ophthalmology Management
10. Adverum Biotechnologies, Inc. - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD